Spyre Therapeutics Reports Third-Quarter 2026 Financial Results and Corporate Update
Story updates
09:07:06 PM UTC
SquawkNews
Spyre Therapeutics: Nettoverlust im dritten Quartal 2026 weitet sich auf 96.12 Millionen US-Dollar a
09:07:58 PM UTC
SquawkNews
Spyre Therapeutics Q3 net loss widens to $96.12 million Spyre Therapeutics’ third-quarter 2026 n
09:09:20 PM UTC
SquawkNews
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is enrolling ahead of schedule, enabling the Company to increase enrollment and pr…
09:13:33 PM UTC
SquawkNews
Spyre Therapeutics reported a net loss of $96.1 million for the third quarter of 2026, compared with a $11.2 million loss in the prior-year quarter. The wider loss primarily reflected a $41.4 million year-over-year swing in other expense or income, mainly due to revaluations of contingent value rig…